TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: Cohort 1; Type: N/A; Interventions: N/A | Arm Label: Cohort 2; Type: N/A; Interventions: N/A
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
C: Arm Label: Methylprednisolone + Standard treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone | Arm Label: Full-dose heparin + Standard treatment; Type: EXPERIMENTAL; Interventions: Drug: Heparin | Arm Label: Methylprednisolone + Full-dose heparin + Standard treatment; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone, Drug: Heparin | Arm Label: Standard treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): Methylprednisolone + Full-dose heparin + Standard treatment, Methylprednisolone + Standard treatment | Intervention Type: DRUG; Name: Heparin; Assigned to Arm(s): Full-dose heparin + Standard treatment, Methylprednisolone + Full-dose heparin + Standard treatment
D: Arm Label: LMWH group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: LMWH + steroids group; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin, Drug: Methylprednisolone | Arm Label: UFH + steroid group; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone, Drug: unfractionated heparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): LMWH + steroids group, LMWH group | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): LMWH + steroids group, UFH + steroid group | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): UFH + steroid group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: LMWH group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: LMWH + steroids group; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin, Drug: Methylprednisolone | Arm Label: UFH + steroid group; Type: EXPERIMENTAL; Interventions: Drug: Methylprednisolone, Drug: unfractionated heparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): LMWH + steroids group, LMWH group | Intervention Type: DRUG; Name: Methylprednisolone; Assigned to Arm(s): LMWH + steroids group, UFH + steroid group | Intervention Type: DRUG; Name: unfractionated heparin; Assigned to Arm(s): UFH + steroid group
B: Arm Label: Prophylactic enexaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Therapeutic Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Prophylactic enexaparin, Therapeutic Enoxaparin
C: Arm Label: Thromboprophylaxis; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin Prefilled Syringe [Lovenox] | Intervention Type: DRUG; Name: Enoxaparin Prefilled Syringe [Lovenox]; Assigned to Arm(s): Thromboprophylaxis
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Dabigatran; Type: EXPERIMENTAL; Interventions: Drug: Dabigatran | Arm Label: Warfarin (INR of 2.0-3.0); Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Dabigatran; Assigned to Arm(s): Dabigatran | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin (INR of 2.0-3.0)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
B: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA
C: Arm Label: dabigatran etexilate 150 mg; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg | Arm Label: warfarin (INR 2-3); Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin (INR 2-3) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg; Assigned to Arm(s): dabigatran etexilate 150 mg | Intervention Type: DRUG; Name: warfarin (INR 2-3); Assigned to Arm(s): warfarin (INR 2-3)
D: Arm Label: Arm 4; Type: ACTIVE_COMPARATOR; Interventions: Drug: (LMW) Heparin + Vitamin K Antagonist | Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Drug: Xarelto (Rivaroxaban, BAY59-7939) | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Xarelto (Rivaroxaban, BAY59-7939); Assigned to Arm(s): Arm 3 | Intervention Type: DRUG; Name: (LMW) Heparin + Vitamin K Antagonist; Assigned to Arm(s): Arm 4

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: dabigatran etexilate 150 mg BID; Type: EXPERIMENTAL; Interventions: Drug: dabigatran etexilate 150 mg twice daily (BID) | Arm Label: matching placebo twice daily (BID); Type: PLACEBO_COMPARATOR; Interventions: Drug: matching placebo twice daily (BID) | Intervention Type: DRUG; Name: dabigatran etexilate 150 mg twice daily (BID); Assigned to Arm(s): dabigatran etexilate 150 mg BID | Intervention Type: DRUG; Name: matching placebo twice daily (BID); Assigned to Arm(s): matching placebo twice daily (BID)
B: Arm Label: heparin/edoxaban tosylate; Type: EXPERIMENTAL; Interventions: Drug: edoxaban tosylate(DU-176b), Drug: low molecular weight heparin/unfractionated heparin | Arm Label: heparin/warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: low molecular weight heparin/unfractionated heparin, Drug: warfarin | Intervention Type: DRUG; Name: edoxaban tosylate(DU-176b); Assigned to Arm(s): heparin/edoxaban tosylate | Intervention Type: DRUG; Name: low molecular weight heparin/unfractionated heparin; Assigned to Arm(s): heparin/edoxaban tosylate, heparin/warfarin | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): heparin/warfarin
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
D: Arm Label: Rivaroxaban (Xarelto, BAY59-7939); Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939) | Arm Label: Enoxaparin/VKA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin overlapping with and followed by VKA | Intervention Type: DRUG; Name: Rivaroxaban (Xarelto, BAY59-7939); Assigned to Arm(s): Rivaroxaban (Xarelto, BAY59-7939) | Intervention Type: DRUG; Name: Enoxaparin overlapping with and followed by VKA; Assigned to Arm(s): Enoxaparin/VKA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reduced-dosed Rivaroxaban and Standard-dosed Rivaroxaban Versus ASA in the Long-term Prevention of Recurrent Symptomatic Venous Thromboembolism in Patients With Symptomatic Deep-vein Thrombosis and/or Pulmonary Embolism
Brief Summary: This is a multicenter, randomized, double-blind, event-driven, superiority study for efficacy.

Patients with confirmed symptomatic DVT (Deep Vein Thrombosis) or PE (Pulmonary embolism) who completed 6 or 12 months of treatment of anticoagulation are eligible for this trial


Options:
A: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Drug: unfractionated Heparin | Intervention Type: DRUG; Name: unfractionated Heparin; Assigned to Arm(s): Intervention group
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Drug: BAY 59-7939 | Arm Label: Arm 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: ASA | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: BAY 59-7939; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: ASA; Assigned to Arm(s): Arm 3
C: Arm Label: Rivaroxaban 10 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Rivaroxaban 10 mg | Arm Label: Best locally standardized care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rivaroxaban 10 mg; Assigned to Arm(s): Rivaroxaban 10 mg
D: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial of Oral Analgesic Utilization for Pain Management of CHildhood Musculoskeletal Injuries
Brief Summary: Pain management for children presenting to the emergency department (ED) with an injured limb is often under-treated, even though it is known that broken arms and legs cause moderate to severe pain. Further, children are less likely to receive appropriate pain medicine than adults with similar injuries. This study aims to improve the pain treatment of children who present to the ED with a suspected fracture, or broken bone or severe sprain. The investigators will compare the use of 3 different possible medication combinations (ibuprofen alone, oral morphine alone, or combined ibuprofen and oral morphine) to determine which combination is the best at treating children's pain. The investigators also plan to verify the safety of using these different drugs to treat children's pain.

The investigators strongly believe that children's pain should be optimally treated in the ED. Adequately relieving children's pain is crucial, as inadequate pain treatment can have both short and longterm effects on the child. It also generates unnecessary stress for both the child and their caregivers/parents. Given this knowledge, the investigators feel that their study has the potential to impact care provided in EDs, and improve pain management safely, for children.


Options:
A: Arm Label: Paracetamol; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol | Arm Label: Dexketoprofen; Type: EXPERIMENTAL; Interventions: Drug: Dexketoprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): Paracetamol | Intervention Type: DRUG; Name: Dexketoprofen; Assigned to Arm(s): Dexketoprofen
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol, Drug: Ibuprofen placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ibuprofen, Drug: Paracetamol Placebo | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Paracetamol, Drug: Ibuprofen | Intervention Type: DRUG; Name: Paracetamol; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): 2, 3 | Intervention Type: DRUG; Name: Paracetamol Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ibuprofen placebo; Assigned to Arm(s): 1
C: Intervention Type: DRUG; Name: Lumiracoxib; Assigned to Arm(s): N/A
D: Arm Label: oral morphine and oral ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: oral morphine and oral ibuprofen | Arm Label: morphine and placebo of ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: Oral morphine | Arm Label: ibuprofen and placebo of morphine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oral ibuprofen | Intervention Type: DRUG; Name: oral morphine and oral ibuprofen; Assigned to Arm(s): oral morphine and oral ibuprofen | Intervention Type: DRUG; Name: Oral morphine; Assigned to Arm(s): morphine and placebo of ibuprofen | Intervention Type: DRUG; Name: Oral ibuprofen; Assigned to Arm(s): ibuprofen and placebo of morphine

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Comprehensive Intervention to Evaluate Outcomes AND Cost in Hospitalized Surgical Patients With DM: COACH-DM
Brief Summary: This study is being performed to evaluate whether a comprehensive discharge planning and close follow up for one year can improve clinical outcomes and cut costs of care for patients with poorly controlled diabetes. The study takes a high risk approach and is focused on patients admitted to hospital for elective surgery with HbA1c \>8%. Secondary goals include improving teamwork and communication for clinicians within the team and teaching nurse practitioners and physicians-in-training how to work effectively within interdisciplinary teams. Investigators anticipate that the results of this project may lead to the following benefits: 1) improved health outcomes for surgical patients with diabetes, 2) improved strategies for better communication within interdisciplinary health care teams, and 3) decreased health care costs.


Options:
A: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home Telehealth with Behavioral Education Component | Intervention Type: BEHAVIORAL; Name: Home Telehealth with Behavioral Education Component; Assigned to Arm(s): Intervention
B: Arm Label: Geriatric Diabetes Team Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral | Arm Label: Atention Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Behavioral; Assigned to Arm(s): Geriatric Diabetes Team Intervention
C: Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Continued care; Type: EXPERIMENTAL; Interventions: Other: team-based care | Intervention Type: OTHER; Name: team-based care; Assigned to Arm(s): Continued care
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Health coaching | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Health coaching; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Sodium Polystyrene Sulfonate in the Treatment of Hyperkaliemia in Ambulatory Pre-dialysis Outpatients : a Randomized Triple-blind Placebo-controlled Trial
Brief Summary: The purpose of this trial is to determine if sodium polystyrene sulfonate (SPS) is an effective treatment of mild hyperkalemia in chronic kidney disease patients followed at a pre-dialysis or nephrology outpatient clinic. Subjects will be randomized to one of two treatment arms: 30 g of placebo or SPS to be taken orally once daily for seven days. The change in serum potassium levels will be compared in both treatment groups. The proportion of subjects attaining normokalemia (3.5 to 5.0 mmol/L) after seven days of treatment will also be compared. Finally, side effects will be reported for each treatment arm.


Options:
A: Arm Label: Patiromer Oral Powder Product; Type: EXPERIMENTAL; Interventions: Drug: Patiromer Oral Powder Product | Arm Label: Usual care arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Patiromer Oral Powder Product; Assigned to Arm(s): Patiromer Oral Powder Product
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Zirconium silicate (ZS); Type: EXPERIMENTAL; Interventions: Drug: Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Zirconium silicate (ZS); Assigned to Arm(s): Zirconium silicate (ZS) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Sodium Polystyrene Sulfonate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sodium polystyrene sulfonate | Arm Label: Lactose with carob gum; Type: PLACEBO_COMPARATOR; Interventions: Drug: Lactose with carob gum | Intervention Type: DRUG; Name: Sodium polystyrene sulfonate; Assigned to Arm(s): Sodium Polystyrene Sulfonate | Intervention Type: DRUG; Name: Lactose with carob gum; Assigned to Arm(s): Lactose with carob gum
D: Arm Label: Sodium Zirconium Cyclosilicate (ZS) 5g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 5g | Arm Label: Sodium Zirconium Cyclosilicate (ZS) 10g; Type: EXPERIMENTAL; Interventions: Drug: Sodium Zirconium Cyclosilicate (ZS) 10g | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 5g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 5g | Intervention Type: DRUG; Name: Sodium Zirconium Cyclosilicate (ZS) 10g; Assigned to Arm(s): Sodium Zirconium Cyclosilicate (ZS) 10g | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study
Brief Summary: Children with thalassemia may have high iron levels after receiving blood transfusions. These high iron levels can have damaging effects on the body, especially the heart. Conventionally only chelation therapy was given for prevention of iron buildup in the heart. However, current research has shown that another drug, amlodipine, also helps to slow down the deposition of iron in the heart. This study is designed to see if patients receiving amlodipine along with their regular chelation therapy have a slower rate of iron buildup in the heart when compared with patients who are receiving chelation only.


Options:
A: Arm Label: Standard Chelation & Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Standard Chelation, Drug: Amlodipine | Arm Label: Standard Chelation; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard Chelation | Intervention Type: DRUG; Name: Standard Chelation; Assigned to Arm(s): Standard Chelation, Standard Chelation & Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Standard Chelation & Amlodipine
B: Arm Label: Starch pill; Type: PLACEBO_COMPARATOR; Interventions: Drug: Amlodipine | Arm Label: Amlodipine; Type: EXPERIMENTAL; Interventions: Drug: Amlodipine | Intervention Type: DRUG; Name: Amlodipine; Assigned to Arm(s): Amlodipine, Starch pill
C: Arm Label: Thalassemia; Type: N/A; Interventions: N/A
D: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Deferoxamine, Drug: Deferasirox, Radiation: HIDA | Intervention Type: DRUG; Name: Deferoxamine; Assigned to Arm(s): Single Arm | Intervention Type: DRUG; Name: Deferasirox; Assigned to Arm(s): Single Arm | Intervention Type: RADIATION; Name: HIDA; Assigned to Arm(s): Single Arm

Answer: A